Trials / Completed
CompletedNCT05648266
Serratus Plane Block After Minimally Invasive Mitral Valve Repair
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Patients undergoing minimally invasive mitral valve reconstruction via small thoracotomy are randomized into two groups. The intervention group receives serratus anterior plane block after minimally invasive mitral-valve reconstruction, following 48h infusion with ropivacaine 2% continually. The control group receives a placebo pump without infusion. Primary endpoints are perceived pain using a numeric pain rating scale and opioid consumption during the hospital stay.
Conditions
- Minimal Invasive Cardiac Surgery
- Minimal Invasive Cardiac Surgery Mitral Valve Surgery
- Serratus Anterior Plane Block
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Continous SAPB (Ropivacain) | postoperative SAPB and pain catheter with continous administered (5ml/h Ropivacain 0,2%) for 48h |
| OTHER | institutional standard of care pain medication protocol | institutional standard of care pain medication protocol |
Timeline
- Start date
- 2022-04-01
- Primary completion
- 2024-07-01
- Completion
- 2024-07-01
- First posted
- 2022-12-13
- Last updated
- 2025-10-02
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT05648266. Inclusion in this directory is not an endorsement.